EyePoint Pharmaceuticals Reports Third Quarter Results with EPS Miss and Revenue Beat
EyePoint Pharmaceuticals (EYPT) reported third-quarter financial results characterized by a significant earnings miss alongside a revenue beat. The company posted a GAAP earnings per share (EPS) of -$1.07, missing analyst expectations by $0.15. Despite the loss, quarterly revenue reached $0.8 million, exceeding estimates by $0.57 million, though this represents a 17.5% decline compared to the same period last year. The results follow recent volatility for the company, including setbacks in late-stage clinical trials and rating downgrades. While there is noted upside potential regarding its DME (Diabetic Macular Edema) pipeline, market concerns persist regarding how much financing will be required to sustain development efforts.